Brain science start-up Neuroelectrics uses electricity and a headcap to reduce seizures in patients with epilepsy. Now it needs FDA approval

Brain science start-up Neuroelectrics uses electricity and a headcap to reduce seizures in patients with epilepsy. Now it needs FDA approval


Inside Neuroelectrics, the brain science start-up hoping to curb epilepsy and depression

High up in the hills of Barcelona, brain science start-up Neuroelectrics is developing therapies that it says will improve the lives of people living with brain disease. 

The group manufactures around 400 devices, which it ships to 75 different countries worldwide each year.

Its main product is a headcap, which monitors the brain’s electrical activity and stimulates regions of the brain with mild electrical currents.

Co-founder and CEO Ana Maiques believes it will significantly improve the lives of people suffering with epilepsy.

“In the world, there are 60 million patients suffering from epilepsy and one third of those don’t respond to medication,” Maiques told CNBC Tech: The Edge in an interview.

“These patients usually go into surgery, either a craniotomy — we remove the part of the brain that is creating the seizures — or an implanted device. So Neuroelectrics is bringing this noninvasive solution to try to reduce seizures.”

In a 17-patient study approved by U.S. Food and Drug Administration, the technology demonstrated a median seizure reduction of 41%. Neuroelectrics is pursuing FDA approval by September 2025.

In addition to epilepsy, Maiques and her team are optimistic that the headgear can also be used to treat depression and Alzheimer’s.

“Our devices read the electrical activity of the brain, but also inject electricity. So, the areas that we’re focused on are those that are clearly electric. So, when you have epilepsy, you have an electrical discharge in one area of your brain, so they can really target and help them,” said Roser Sanchez-Todo, R&D director for Neuroelectrics’ brain modelling department.

CNBC senior technology correspondent Arjun Kharpal tries on Neuroelectrics’ neurostimulating electrical headcap.

Benjamin Hall

NeuroTwin

Before a patient can use the technology, Neuroelectrics builds a replica of their brain, known as a NeuroTwin.

“We’ve been using what is now called AI, or machine learning, for years. If you think of flight pilots, they don’t go into planes, they are in simulators. So, why can you not have a simulator of the brain, where you can really have a digital copy of your brain?” Maiques said.

“Then we can say, if we provide you this treatment, or this stimulation, how is your brain going to react? We are very excited about our NeuroTwin technology. I think it’s going to change the way we look at brain diseases,” she added.

The end goal is for patients to be able to use the cap at home, which is essential as it takes ten daily 20-minute sessions for around eight weeks for the average epilepsy patient to feel results.

“Then you just go. You put your headcap on, maybe you need some help in order to put the gel for the electrodes, and you just press the start stimulation,” Sanchez-Todo said.

“Usually, it’s from 20 minutes to an hour that you’re sitting and relaxing. Then you just need to take it out, clean it, and then for the next day you repeat.”



Source

Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.
World

Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.

Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales. Source

Read More
Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts
World

Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts

People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk hiked its annual profit guidance on Wednesday, as the drugmaker said its Wegovy weight-loss pill performed better than expected in the first three months of the […]

Read More
CNBC’s UK Exchange newsletter: It’s not the 1970s, but the oil shock is still biting hard
World

CNBC’s UK Exchange newsletter: It’s not the 1970s, but the oil shock is still biting hard

A sign saying “Sorry, No Petrol” on the forecourt of a BP service station during a fuel shortage in London on Feb 9, 1971. Evening Standard | Hulton Archive | Getty Images This report is from this week’s CNBC’s UK Exchange newsletter. Like what you see? You can subscribe here. The dispatch For Britons of a […]

Read More